The extensive user base that Apple (NASDAQ: AAPL ) has established over the years has the potential to create at least three new sources of revenue for the technology leader. First, as Apple develops its near-field communication capabilities, mobile payments may become more viable. Second, with the release of iTunes Radio, Apple may be able to compete with Pandora (NYSE: P ) and garner more users. Finally, if Apple is able to successfully introduce new advertising capabilities, it may be able to push into Google’s (NASDAQ: GOOG ) turf in mobile ads.
In the following video, Fool.com contributor Doug Ehrman discusses these developments and how iTunes may allow Apple to break into new markets.
There’s no doubt that Apple is at the center of technology’s largest revolution ever and that longtime shareholders have been handsomely rewarded, with more than 1,000% gains. However, there is a debate raging as to whether Apple remains a buy. The Motley Fool’s senior technology analyst and managing bureau chief, Eric Bleeker, is prepared to fill you in on reasons to buy and reasons to sell Apple and what opportunities are left for the company (and your portfolio) going forward. To get instant access to his latest thinking on Apple, simply click here now.
10 Best Oil Service Stocks To Buy For 2015: Sigma-Aldrich Corp (SIAL)
Sigma-Aldrich Corporation, incorporated in May 12, 1975, is a life science and high technology company. The Company develops, manufactures, purchases and distributes the range of chemicals, biochemicals and equipment available globally and also provides global biopharmaceutical testing services. These chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. As of December 31, 2012, the Company offered approximately 45,000 equipment products. On January 31, 2012, the Company completed its acquisition of all of interest of BioReliance, a provider of global biopharmaceutical testing services. On April 2, 2012, the Company acquired Research Organics, a supplier of purity biochemicals.
The Company provides products and services that focus on research customers that use smaller q uantities of its products in basic life science and high-technology research and development (R&D); manufacturing customers that use its products in quantities in lab-stage development and manufacturing; life science customers who use its biopharmaceutical testing services to facilitate the development, manufacturing and commercialization of biological drugs, and industrial and diagnostic companies that use its products in range of forms of assays and testing, as well as in clinical diagnostics. The Company has a customer base of commercial laboratories, pharmaceutical companies, industrial companies, universities, diagnostics companies, biotechnology companies, electronics companies, hospitals, governmental institutions and non-profit organizations located in the United States and globally.
- [By Vanina Egea]
At the beginning of April, the trade alarm for Sigma-Aldrich (SIAL) set off due to a larger seller coming together with the buyers to raise a posted offer. The phenomena pushed up stock face value, however unable to continue the previous trend. Hence, stock value has been on a decline since the month of March. Reasoning about the sources for the stagnation, will give potential investors important insight for a current or future investment. Given the nature of the firm, close attention should be paid to research and development. But, most importantly, to the business model as a whole and market environment. Looking at recent full year reports can also offer important information about specific performance indicators. In the middle, there is an important number of new positions consolidated by gurus through 2013, who would like to see new investors enter the business.
- [By Maxx Chatsko]
Any company that creates products and relies on other companies to use and distribute them will inevitably forge strong relationships with its customers. It’s an important thing to look into when investing, yet easy to overlook. Investors should know whether customers are reliable, which are leaned on the most, and if the company they own is too dependent on any customer (or a select few). Bioprocessing product company Repligen (NASDAQ: RGEN ) may make consumables that are the lifeline of the biotech industry, but its customer relationships are absolutely critical for smooth operations. Let’s look at how the company interacts with the Life Sciences division of General Electric (NYSE: GE ) , EMD Millipore from Merck (NYSE: MRK ) , and Sigma-Aldrich (NASDAQ: SIAL ) — the three most important customers.
- [By Monica Gerson]
Sigma-Aldrich (NASDAQ: SIAL) is expected to report its Q3 earnings at $0.99 per share on revenue of $661.29 million.
CR Bard (NYSE: BCR) is projected to post its Q3 earnings at $1.40 per share on revenue of $739.62 million.
- [By Nicole Seghetti]
2. Sigma-Aldrich (NASDAQ: SIAL )
Maker of test tubes and beakers, Sigma-Aldrich has increased its dividend every year since 1976. Even though the company pays a relatively scrawny 1.1% dividend yield, its 21% payout ratio signals the company has ample opportunity to up its dividend for many years to come.
10 Best Oil Service Stocks To Buy For 2015: North American Oil & Gas Corp (NAMG)
Calendar Dragon Inc., incorporated on April 7, 2010, is a development-stage company. The Company was formed to create a new calendaring tool that incorporates a range of features not offered by other providers, all in one lean online package. Its Website www.calendardragon.com was formed to bridge the gap between current social networking, e-mail and calendaring / scheduling activities for the individual, with applications to business, government, law enforcement, and medical.
The calendardragon.com Website focuses on having each of the various windows within the interface: Contacts like an email app, traditional left location; Events & to do lists along with ability to hide / show events and to do lists with others; Calendar customizable view; Message text (thread), along with list of participants in a separate pane, and Options. During the fiscal year ended November 30, 2010, the Company did not generate any revenue.
- [By Peter Graham]
What’s the Catch With New Western Energy Corp? According to various disclosures, transactions of $3k and $4k have or will occur to mention New Western Energy Corp in various investment newsletters. Last Tuesday, New Western Energy Corp announced it had drilled the Anna #1 well to 1,793 ft. and the presence of coal gas was confirmed. If the quantity of gas is sufficient, the New Western Energy Corp will construct a gas gathering pipeline for no more than $200k to connect the field to the nearest sales point. Investors should be aware that the New Western Energy Corp has reported revenues of $19k (most recent reported quarter), $31k, $24k and $15k for the past four quarters along with net losses of $181k (most recent reported quarter), $1,025k, $106k and $110k. Nevertheless and at the end of March, New Western Energy Corp had $793k in cash to cover $521k in current liabilities. That could be enough cash to sustain the company until it gets more revenue pumping in.
North American Oil & Gas Corp (OTCBB: NAMG) Has Announced a Completed Strategic Review
Small cap North American Oil & Gas Corp is focused on the prolific San Joaquin Basin in onshore California with existing foundation assets targeting exploration and exploitation of high impact oil and gas projects located near infrastructure and existing discoveries. On Friday, North American Oil & Gas Corp fell 1.05% to $0.940 for a market cap of $56.52 million plus NAMG is up 276% since November 2012 according to Google Finance.
10 Best Oil Service Stocks To Buy For 2015: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company’s work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company’s program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tum or cells.
The Company’s pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson’s Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkin son’s disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company’s antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.Advisors’ Opinion:
- [By Jake L’Ecuyer]
Prothena Corporation (NASDAQ: PRTA) shares were down as well, falling 28.00 percent to $27.13 after the company released some materials from its coming symposium presentation.
- [By Jake L’Ecuyer]
Shares of Prothena Corporation plc (NASDAQ: PRTA) got a boost, shooting up 6.99 percent to $32.00 after the company reported the successful start of a Phase 1 clinical trial of PRX002 for the treatment of Parkinson’s disease. Citigroup initiated coverage on the stock with a Buy rating and a $50.00 price target.
- [By Jake L’Ecuyer]
Equities Trading UP
Prothena Corporation plc (NASDAQ: PRTA) shares shot up 21.60 percent to $45.19 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
10 Best Oil Service Stocks To Buy For 2015: Chicago Bridge & Iron Company NV (CBI)
Chicago Bridge & Iron Company N.V. (CB&I) is one of the integrated engineering, procurement and construction (EPC) services providers and process technology licensors, delivering solutions to customers primarily in the energy, petrochemical and natural resource industries. CB&I consist of three business sectors: Steel Plate Structures, Project Engineering and Construction, and Lummus Technology. Through these business sectors, the Company offers services both independently and on an integrated basis.
As of December 31, 2012, the Company had more than 900 projects in process in more than 70 countries. On February 13, 2013, it acquired The Shaw Group Inc. (Shaw).
Steel Plate Structures
Steel Plate Structures provides engineering, procurement, fabrication and construction services, including mechanical erection services, for the hydrocarbon, water and nuclear industries. Projects include above ground storage tanks, elevated stor age tanks, Liquefied Natural Gas (LNG) tanks, pressure vessels, and other specialty structures, such as nuclear containment vessels. Customers include international energy companies, such as Chevron, ConocoPhillips, ExxonMobil and Shell; national energy companies, such as ADNOC (Abu Dhabi), CNOOC (China) and Saudi Aramco (Saudi Arabia); and regional energy companies, such as Kinder Morgan (United States) and Suncor (Canada).
Project Engineering and Construction
Project Engineering and Construction provides engineering, procurement, fabrication and construction services for upstream and downstream energy infrastructure facilities. Projects include LNG liquefaction and regasification terminals, gas processing plants, refinery units, petrochemical complexes and a wide range of other energy-related projects. Customers include international energy companies, such as British Petroleum, Chevron, ConocoPhillips, ExxonMobil and Shell; national energy compani es, such as Ecopetrol (Colombia) and ORPIC (Oman); and regio! nal energy companies, such as Dominion (United States), Gazprom (Russia), Nexen (United Kingdom), and Woodside (Australia).
Lummus Technology provides licenses, services, catalysts and equipment for the hydrocarbon refining, petrochemical, and gas processing industries. Customers include international energy companies, such as Chevron and Shell; national energy companies, such as Pemex (Mexico), Petrochina (China), Rosneft (Russia) and Sabic (Saudi Arabia); and regional refiners and chemical and gas processing companies, such as China Coal (China), IRPC (Thailand), Kazakhstan Petrochemical (Kazakhstan), and Williams Energy Services (United States).
Power provides a range of services, including design, EPC, technology and consulting services, primarily to the fossil and nuclear power generation industries. Plant Services provides electric power refueling outage maintenance, turnaround maintenance, routine maintenance, o ffshore maintenance, modifications, capital construction, off-site modularization, fabrication, reliability engineering, plant engineering, plant support and specialty services. Additionally, it provides services to restore, rebuild, repair, renovate and modify industrial and electric power generation facilities, and offers predictive and preventive maintenance services. Environmental & Infrastructure (E&I) provides full-scale environmental and infrastructure services for government and private-sector clients. These services include program and project management, design-build, engineering and construction, sustainability and energy efficiency, remediation and restoration, science and technology, facilities management and emergency response and disaster recovery. Fabrication and Manufacturing is a worldwide supplier of fabricated piping systems primarily to the electric power, petrochemical and refinery industries, supporting both external clients and other Shaw business sec tors.
- [By MONEYMORNING.COM]
We’ve found such a company: Chicago Bridge & Iron Company NV (NYSE: CBI). And we believe the time to move on this stock is now.
Here’s why …
- [By MONEYMORNING.COM]
We’ve found such a company: Chicago Bridge & Iron Co. NV (NYSE: CBI). And we believe the time to move on this stock is now.
Here’s why …
- [By Myra Ramdenbourg]
Chicago Bridge and Iron Company (CBI): Executive Vice President and CFO Ronald A Ballschmiede sold 18,471 Shares
On 02/24/2014, Executive Vice President and CFO Ronald A Ballschmiede sold 18,471 shares at an average price of $80.38. The price of the stock has increased by 5.82% since. Chicago Bridge and Iron Company has a market cap of $9.13 billion and its shares were traded at around $85.06. The company has a P/E ratio of 20.60 and P/S ratio of 0.82 with a dividend yield of 0.26%. Over the past 10 years, Chicago Bridge and Iron Company had an annual average earnings growth of 24.30%. GuruFocus rated Chicago Bridge & Iron Company the business predictability rank of 2.5-star.
- [By Aaron Levitt]
That’s why the stocks to buy could be the construction and engineering firms that focus on building energy infrastructure. Here are three of the best stocks to buy for America’s upcoming infrastructure boom:
3 Stocks To Buy Chicago Bridge & Iron Company (CBI)
While it’s not based in Chicago and it doesn’t build bridges, Chicago Bridge & Iron Company (CBI) could be one of the best energy infrastructure stocks to buy for building out America’s shale boom. The firm is a petrochemical construction powerhouse and has been involved in a variety petroleum-related projects — including the design and construction of some of the world’s largest onshore and offshore pipeline projects, LNG facilities and refineries.
10 Best Oil Service Stocks To Buy For 2015: Starwood Hotels & Resorts Worldwide Inc.(HOT)
Starwood Hotels & Resorts Worldwide Inc. operates as a hotel and leisure company worldwide. The company operates luxury and upscale full service hotels, select-service hotels, extended stay hotels, resorts, retreats, and residences under St. Regis, The Luxury Collection, W, Westin, Le M